Anti-c5 antibodies and uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsYing Hu, Adrianna Latuszek, Carmelo Romano, William Olson
Life of this patent
Estimating the term…
Abstract
The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.
Claims25
1-32. (canceled)
A method of treating or ameliorating at least one symptom or indication of a disease or disorder associated with C5 in a human subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or antigen-binding fragment thereof that specifically binds C5 comprising
- a heavy chain variable region that comprises
- an HCDR1 that comprises an amino acid sequence as set forth in SEQ ID NO:
- 100,
- an HCDR2 that comprises an amino acid sequence as set forth in SEQ ID NO:
- 102, and
- an HCDR3 that comprises an amino acid sequence as set forth in SEQ ID NO:
- 104;
- and a light chain variable region that comprises
- an LCDR1 that comprises an amino acid sequence as set forth in SEQ ID NO:
- 108,
- an LCDR2 that comprises an amino acid sequence as set forth in SEQ ID NO:
- 110, and
- an LCDR3 that comprises an amino acid sequence as set forth in SEQ ID NO:
- 112;
- to the human subject.
(canceled)
Dependencies are inferred from the claim text.